🇺🇸 FDA
Patent

US 10494382

Crystalline solvate comprising 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile, methanol, N-N-dimethylformamide, and water

granted A61KA61K31/46A61K45/06

Quick answer

US patent 10494382 (Crystalline solvate comprising 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile, methanol, N-N-dimethylformamide, and water) held by Theravance Biopharma R&D IP, LLC expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/46, A61K45/06, A61P, A61P1/00